US Stock MarketDetailed Quotes

AVTE Aerovate

Watchlist
  • 22.050
  • +0.450+2.08%
Close Apr 19 16:00 ET
  • 22.050
  • 0.0000.00%
Post 16:03 ET
614.38MMarket Cap-7682P/E (TTM)

About Aerovate Company

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

Company Profile

SymbolAVTE
Company NameAerovate
Listing DateJun 30, 2021
Issue Price14.00
Founded2018
CEOMr. Timothy P. Noyes
MarketNASDAQ
Employees51
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address930 Winter Street,Suite M-500
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02451
Phone1-617-443-2400

Company Executives

  • Name
  • Position
  • Salary
  • Timothy P. Noyes
  • Director and Chief Executive Officer
  • 703.80K
  • Timothy Pigot
  • Chief Commercial Officer
  • --
  • Dr. Benjamin T. Dake, PhD
  • President, Chief Operating Officer and Secretary
  • 502.12K
  • George A. Eldridge
  • Chief Financial Officer, Treasurer and Principal Accounting Officer
  • 533.89K
  • Dr. Hunter Gillies, M.B.
  • Chief Medical Officer
  • 423.44K
  • Ralph Niven,PhD
  • Chief Scientific Officer
  • --
  • Dr. Marinus Verwijs, PhD
  • Senior Vice President, CMC
  • 1.26M
  • Mark T. Iwicki
  • Chairman of the Board
  • 184.25K
  • Allison Dorval
  • Independent Director
  • 151.75K
  • Dr. Maha Katabi, PhD
  • Independent Director
  • 151.63K
  • Dr. Joshua Resnick, M.D.
  • Independent Director
  • 140.75K
  • Donald J. Santel
  • Independent Director
  • --
  • Dr. David S. Grayzel, M.D.
  • Independent Director
  • 152.16K
  • Habib Joseph Dable
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg